Saturday 17 October 2026
Export VCEL’s income statement to Excel — free account
Vericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024. In the quarter to June 2026, revenue grew 22.5%, EPS grew 500.0% and free cash flow grew 17,503.7%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
40.13
0.89
−2.17%
Follow VCEL
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
112.53 | 274.55 | 0.00 | 0.00 | 0.00 | 441.14 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
7 | 6 | 5 | 3 | 6 | 5 | 4 | 5 | 4 | 3 |
P/S ratio |
6.56 | 11.31 | 8.40 | 7.21 | 11.69 | 11.25 | 6.52 | 7.71 | 3.08 | 1.23 |
Altman Z-Score |
8.21 | 11.20 | 7.41 | 8.23 | 13.95 | 10.42 | 8.73 | 22.82 | (4.76) | (7.56) |
P/FCF ratio |
73.25 | 0.00 | 212.87 | 117.37 | 86.45 | 93.43 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
3.10 | 1.75 | 0.98 | 0.89 | 0.66 | (0.68) | (1.85) | 1.58 | (18.16) | (20.32) |
Beneish M-Score |
(2.53) | (2.86) | (2.53) | (2.99) | (3.15) | (2.52) | (2.25) | (2.25) | (2.79) | (2.53) |
P/Operating CF |
120.74 | 120.59 | 164.58 | 169.80 | 173.10 | 123.17 | 244.04 | 268.18 | 235.96 | (7.19) |
P/B ratio |
5.11 | 9.19 | 7.35 | 6.16 | 10.71 | 10.40 | 6.92 | 6.85 | 8.73 | 0.00 |
Price to Tangible BV |
5.19 | 9.39 | 7.58 | 6.41 | 10.89 | 10.62 | 7.09 | 7.04 | 9.92 | 0.00 |
EV/Sales |
6.13 | 10.85 | 7.85 | 6.58 | 11.14 | 10.77 | 6.08 | 6.98 | 2.93 | 0.99 |
EV/EBITDA |
74.82 | 268.53 | 0.00 | 0.00 | 0.00 | 263.73 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
32.61 | 44.23 | 43.89 | 61.18 | 59.93 | 76.14 | (99.72) | (1,540.21) | (14.20) | (2.72) |
EV/FCF |
68.39 | (442.74) | 198.75 | 107.24 | 82.38 | 89.52 | (73.10) | (205.36) | (12.74) | (2.54) |
Quick Ratio |
4.52 | 3.74 | 4.06 | 4.43 | 5.41 | 4.91 | 5.15 | 7.19 | 3.45 | 3.12 |
Current Ratio |
5.03 | 4.23 | 4.49 | 4.99 | 6.08 | 5.50 | 5.64 | 7.62 | 3.86 | 3.48 |
Net Debt/EBITDA |
(6.08) | (13.23) | 52.17 | 9.28 | 26.24 | (14.94) | 6.89 | 29.51 | 0.72 | 0.88 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 31.58% | 20.78% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.76 | 0.41 |
Asset Turnover |
0.60 | 0.60 | 0.63 | 0.64 | 0.70 | 0.69 | 0.87 | 1.05 | 1.24 | 1.31 |
Operating CF/Net income |
3.14 | 5.61 | (11.10) | (1.06) | (3.89) | 6.14 | 0.74 | 0.05 | 0.76 | 1.02 |
Capex/Depreciation |
(2.35) | (12.64) | (6.84) | (1.82) | (2.02) | (0.97) | (2.31) | (2.44) | (0.94) | (0.31) |
Interest Coverage |
17.53 | 7.36 | (10.77) | (46.61) | (1,963.50) | 395.33 | (1,406.37) | (2.26) | (13.54) | (61.29) |
| 5.11% | 4.00% | (1.52%) | (9.21%) | (4.90%) | 2.33% | (9.06%) | (13.04%) | (390.25%) | 118.26% | |
| 3.59% | 2.64% | (1.02%) | (6.47%) | (3.33%) | 1.60% | (7.11%) | (9.39%) | (33.51%) | (47.20%) | |
ROIC |
3.18% | 1.71% | (4.10%) | (14.66%) | (7.32%) | 2.54% | (17.00%) | (12.65%) | (72.51%) | (101.70%) |
Return on Tangible Assets |
5.39% | 3.90% | (1.58%) | (10.11%) | (5.13%) | 2.63% | (9.76%) | (7.83%) | (41.67%) | (54.74%) |
Average Days of Receivables |
111.82 | 94.43 | 107.84 | 103.35 | 87.49 | 101.42 | 99.63 | 94.22 | 104.32 | 114.72 |
Research and Development Expense of Revenue |
9.98% | 10.45% | 10.65% | 12.13% | 10.43% | 10.48% | 25.79% | 14.97% | 20.25% | 28.12% |
Selling, General and Administrative Expense of Revenue |
60.45% | 60.19% | 61.26% | 65.04% | 62.49% | 55.43% | 51.88% | 53.94% | 55.71% | 50.36% |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.02 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
14.03% | 15.38% | 16.37% | 22.62% | 21.98% | 11.15% | 11.18% | 7.95% | 4.19% | 4.60% |
Graham Net Nets |
0.06 | 0.03 | 0.05 | 0.09 | 0.05 | 0.04 | 0.09 | 0.14 | 0.09 | 0.31 |
Graham Number |
7.12 | 5.19 | 0.00 | 0.00 | 0.00 | 2.16 | 0.00 | 0.00 | 0.00 | 3.68 |
Earnings Yield |
0.89% | 0.36% | (0.23%) | (1.39%) | (0.41%) | 0.23% | (1.32%) | (1.32%) | (8.98%) | (35.02%) |
Free Cash Flow Yield |
1.37% | (0.22%) | 0.47% | 0.85% | 1.16% | 1.07% | (1.27%) | (0.44%) | (7.47%) | (31.82%) |
Revenue per Share |
5.49 | 4.86 | 4.15 | 3.49 | 3.36 | 2.75 | 2.67 | 2.26 | 1.92 | 2.36 |
Operating CF per Share |
1.03 | 1.19 | 0.74 | 0.38 | 0.62 | 0.39 | (0.16) | (0.01) | (0.40) | (0.86) |
Capex per Share |
(0.54) | (1.31) | (0.58) | (0.16) | (0.17) | (0.06) | (0.06) | (0.07) | (0.05) | (0.06) |
Free Cash Flow per Share |
0.49 | (0.12) | 0.16 | 0.21 | 0.45 | 0.33 | (0.22) | (0.08) | (0.44) | (0.92) |
Cash per Share |
2.73 | 2.59 | 2.68 | 2.54 | 2.23 | 1.68 | 1.58 | 2.06 | 0.81 | 1.00 |
Shareholders Equity per Share |
7.04 | 5.98 | 4.75 | 4.08 | 3.67 | 2.97 | 2.51 | 2.54 | 0.68 | 1.07 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
7.04 | 5.98 | 4.75 | 4.08 | 3.67 | 2.97 | 2.51 | 2.54 | 0.68 | 1.07 |
Free Cash Flow |
24.75 | (5.81) | 7.80 | 10.09 | 21.13 | 14.95 | (9.80) | (3.09) | (14.69) | (21.31) |
Working Capital |
198.29 | 162.49 | 159.88 | 149.40 | 132.41 | 101.08 | 91.86 | 97.99 | 37.42 | 31.87 |
Capital Expenditures |
(27.16) | (63.97) | (27.51) | (7.60) | (7.91) | (2.63) | (2.62) | (2.68) | (1.51) | (1.41) |
Net Current Asset Value |
114.11 | 72.02 | 77.93 | 106.14 | 85.22 | 52.21 | 69.51 | 96.33 | 18.47 | 20.83 |
EV/EBIT |
153.25 | 569.33 | 0.00 | 0.00 | 0.00 | 564.04 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.10 | 0.27 | 0.14 | 0.05 | 0.05 | 0.02 | 0.02 | 0.03 | 0.02 | 0.03 |
Price to Operating Income |
164.14 | 593.55 | 0.00 | 0.00 | 0.00 | 588.71 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.11 | 0.05 | 0.10 | 0.26 | 0.29 | 0.35 | 0.16 | 0.19 | 0.40 | 1.17 |
Cash ROIC |
5.03% | (1.39%) | 2.21% | 3.24% | 7.71% | 7.11% | (5.42%) | (1.67%) | (22.05%) | (36.87%) |
Accounts Receivable Turnover |
3.78 | 3.96 | 3.77 | 3.91 | 4.34 | 3.73 | 4.24 | 4.36 | 3.62 | 3.88 |
Accounts Payable Turnover |
3.56 | 2.82 | 3.15 | 4.21 | 6.36 | 6.10 | 5.59 | 5.08 | 5.02 | 4.01 |
Inventory Turnover |
4.05 | 4.28 | 4.26 | 3.72 | 4.41 | 4.94 | 7.24 | 8.75 | 8.34 | 11.63 |
Average Days of Payables |
81.76 | 133.68 | 131.69 | 113.22 | 65.61 | 61.72 | 61.64 | 80.67 | 66.76 | 84.26 |
Days of Inventory on Hand |
90.71 | 97.38 | 77.12 | 106.91 | 97.37 | 85.48 | 66.22 | 40.38 | 45.61 | 44.98 |
Average Receivables |
73.00 | 59.87 | 52.45 | 41.99 | 35.97 | 33.34 | 27.81 | 20.86 | 17.68 | 14.01 |
Average Payables |
19.84 | 23.10 | 19.64 | 12.97 | 7.89 | 6.55 | 6.73 | 6.33 | 6.04 | 7.06 |
Average Inventory |
17.47 | 15.23 | 14.54 | 14.68 | 11.37 | 8.09 | 5.19 | 3.68 | 3.64 | 2.43 |
Average Assets |
460.35 | 393.19 | 313.33 | 258.35 | 224.66 | 179.42 | 135.96 | 86.63 | 51.59 | 41.45 |
Average Common Equity |
323.30 | 258.96 | 209.11 | 181.37 | 152.36 | 122.68 | 106.66 | 62.39 | 4.43 | (16.54) |
Columns are period end dates